louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01232231: Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting
Official title: Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus in the Outpatient Setting: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Methicillin-resistant Staphylococcus Aureus
Keywords: methicillin-resistant Staphylococcus aureus
decolonization
random allocation
outpatient
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: Alberta Health services
First posted: 2010-11-02
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effectiveness of topical and oral antibiotics in eliminating carriage of methicillin-resistant Staphylococcus aureus (MRSA) among those living in the community. We hypothesize that a greater proportion of those who receive intervention will eliminate MRSA carriage compared to those who do not receive any intervention.


Eligibility criteria: Inclusion Criteria:

* Prior MRSA infection (i.e index case)
* Identified as being colonized with MRSA on initial screen

Exclusion Criteria:

* Are pregnant or breastfeeding.
* Have indwelling catheters.
* Received prior decolonization treatment within last 6 months of enrollment.
* Have allergy to study medication.
* Are colonized with MRSA strain resistant to study medication.
* Have active infection requiring systemic antimicrobials.
* Are household contacts to index case.

Primary outcomes:
measure: Eradication of MRSA carriage
timeFrame: 90 days after randomization
Secondary outcomes:
measure: Occurrence of MRSA infection
timeFrame: Within 6 months of randomization
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Foothills Medical Center
state: Alberta
Study officials:
affiliation: University of Calgary
name: Thomas J Louie, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00655031: Trial to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection
Official title: A Placebo Controlled, Randomized, Double Blind Pilot Study to Evaluate the Use of Pomegranate Concentrate (POMx) for the Prevention of Experimental Rhinovirus Infection in Human Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Common Cold
Keywords: Punicaceae
Pomegranate
Lead sponsor: POM Wonderful LLC
Sponsor class: INDUSTRY
First posted: 2008-04-09
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Pomegranate has a long history of use in folk medicine. There is vast data on the health benefits of pomegranate fruit and juice. Multiple studies have established the strong antioxidative effects of pomegranate polyphenols (primarily the ellagitannin punicalagin) and their health effects. A vast number of animal and human clinical studies have provided evidence on effect of pomegranate products on reducing symptoms of common cold, reducing blood pressure, improving endothelial function, anti-tumor activity, and its anti-atherosclerotic activity. This study will evaluate the protective effect of a pomegranate concentrate (POMx) in decreasing the incidence and duration of the common cold among healthy adults.


Eligibility criteria: Inclusion Criteria:

* Nonsmoker
* No recent history of respiratory disease

Exclusion Criteria:

* Serum positive for rhinovirus
* Pregnant or breastfeeding
* Recent immunization

Primary outcomes:
measure: The proportion of subjects who become infected in the active treatment group compared with the proportion of subjects who become infected in the placebo treatment group.
timeFrame: Days 1-5
Secondary outcomes:
measure: Comparison of symptom scores in the treatment groups
timeFrame: Days 1-5
measure: Determination of effects of treatment on immune function.
timeFrame: Days 1-5
Other outcomes:
Locations:
city: Huntsville
country: United States
facility: Accelovance Inc.
state: Alabama
city: Melbourne
country: United States
facility: Accelovance Inc
state: Florida
city: Charlottesville
country: United States
facility: University of Virginia School of Medicine
state: Virginia
Study officials:
affiliation: University of Virginia
name: Ronald B Turner, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01762631: Remote Food Photography Method in Infants
Official title: Baby Bottle: Remote Food Photography Method in Infants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Estimating Infant Food Intake
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2013-01-08
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Up to 75 men and women will be recruited to participate in a 2-week pilot study involving infant formula preparation. Participation is open to all adult individuals.

Brief summary: The purpose of this study is to determine if digital photography on a Smartphone and the Remote Food Photography Method (RFPM) can estimate infant formula intake. This is a validation study; there is no hypothesis.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years of age
* Willing to complete 2 study visits at Pennington Biomedical (PBRC)

Primary outcomes:
measure: Kilocalorie (Kcal) Difference Between Methods for All Prepared Bottles
timeFrame: Measures will be performed twice about 5-10 days apart
Secondary outcomes:
measure: Kilocalorie (Kcal) Difference Between Different Bottle Sizes
timeFrame: Measures will be performed twice about 5-10 days apart
Other outcomes:
measure: Gram Weight of Infant Formula Provision Between Participants Who Identified as Infant Caregivers and Infant Non-caregivers for 2 oz Prepared Bottles Only
timeFrame: Measures will be performed twice about 5-10 days apart
measure: Gram Weight of Infant Formula Provision Between Participants Who Identified as Infant Caregivers and Infant Non-caregivers for 4 oz Prepared Bottles Only
timeFrame: Measures will be performed twice about 5-10 days apart
measure: Gram Weight of Infant Formula Provision Between Participants Who Identified as Infant Caregivers and Infant Non-caregivers for 6 oz Prepared Bottles Only
timeFrame: Measures will be performed twice about 5-10 days apart
measure: Gram Weight of Infant Formula Provision Between Participants Who Identified as Infant Caregivers and Infant Non-caregivers for 8 oz Prepared Bottles Only
timeFrame: Measures will be performed twice about 5-10 days apart
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
affiliation: Pennington Biomedical Research Center
name: Leanne M Redman, Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Pennington Biomedical Research Center
name: Corby Martin, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00036231: Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Autism
Lead sponsor: Repligen Corporation
Sponsor class: INDUSTRY
First posted: 2002-05-09
Sex: ALL
Minimum age (years): 32
Maximum age (years): 59
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine the effect of multiple doses of secretin on autism.


Eligibility criteria: * Autism
* Gastrointestinal dysfunction

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01867931: Epithelial Damage in GERD
Official title: Characterisation of Esophageal Epithelial Damage in Patients With Non-erosive Reflux Disease (NERD) and Erosive Esophagitis (EE): Role of Epithelial Permeability
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastro-esophageal Reflux Disease
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2013-06-04
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with EE and patients with NERD referred to the GI-outpatient clinic of the University Hospital Maastricht with an indication for diagnostic gastroscopy, as well healthy volunteers will be asked to participate in the study.

Brief summary: The purpose of this study is to characterize and compare epithelial damage in patients with erosive esophagitis and non-erosive reflux disease.


Eligibility criteria: Inclusion Criteria:

* Typical GERD-symptoms lasting for more than 6 months (recurrent episodes of heartburn or acid regurgitation)
* abnormal pH-parameters (pathological acid exposure and/or symptom association)

Exclusion Criteria:

* Age \<18 years
* Previous esophageal or gastric surgery
* Severe esophageal motility disorder on manometry
* Histological evidence of Barrett's mucosa
* Severe co-morbidities (including cardiopulmonary disease, portal hypertension, collagen diseases, morbid obesity, coagulation disorders and co-morbidity hindering a gastroscopic procedure)
* Use of anticoagulant or immunosuppressive drugs
* Inability to stop medication that can influence the test results, like PPI, for at least 10 days before tests
* Excessive alcohol consumption (\>20 units per week)
* Patients unable to give informed consent.

Primary outcomes:
measure: Epithelial integrity in tissue biopsies
timeFrame: 1 year
Secondary outcomes:
measure: Immunohistochemical markers in tissue biopsies
timeFrame: 1 year
measure: Histological changes in tissue biopsies
timeFrame: 1 year
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
Study officials:
affiliation: Maastricht University Medical Center
name: J.M. Conchillo, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jovov B, Que J, Tobey NA, Djukic Z, Hogan BL, Orlando RC. Role of E-cadherin in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2011 Jun;106(6):1039-47. doi: 10.1038/ajg.2011.102. Epub 2011 Mar 29.
citation: Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005 Mar;128(3):771-8. doi: 10.1053/j.gastro.2004.08.014.
Clinical trial NCT02468531: Xenon Against Postoperative Oxygen Impairment
Official title: Protection of Xenon Against Postoperative Oxygen Impairment in Adults Undergoing Stanford Type-A Acute Aortic Dissection Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Lung Injury
Keywords: Xenon
Standford A acute aortic dissection
Lead sponsor: Beijing Anzhen Hospital
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Acute lung injury (ALI) is the vital complication of Stanford type A aortic dissection. It is confirmed that Xenon has the significant protective effect on important organs and has no suppression on the cardiovascular system. Furthermore, our earlier trial has already clarified that static inflation with 50% Xenon during cardiopulmonary bypass could attenuate ALI for Standford A acute aortic dissection. However the protection effect was restricted for the limited time. Aimed to enhance the protection effect of Xenon, we designed this randomized trial that anesthesia with 50% xenon one hour before and after CPB and pulmonary static Inflation with 50%,75% and 100% Xenon during CPB respectively.


Eligibility criteria: Inclusion Criteria

Consultant's clinical diagnosis of Stanford type A AAD using local pathways of diagnosis, which may include clinical history, chest radiography (X-rays), transthoracic ultrasound, and contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI)

Patients aged 18 to 65 years

Eligible for AAD surgery

Exclusion Criteria

Have coronary heart disease, heart failure, severe cardiac tamponade, unstable hemodynamics, severe nervous system abnormalities, clinically apparent malperfusion\[9\] including lower limb, cerebral, coronary and renal malperfusion, and visceral ischemia, sever hepatic and renal abnormalities

Have undergone any of the cardiac and thoracic surgeries

Are unlikely to be able to perform the required clinical assessment tasks

Have significant cognitive impairment or language issues

Are unable to provide consent with regard to their participation in the study

Prescribed with non-steroidal anti-inflammatory drugs or corticosteroids before or after admission

Primary outcomes:
measure: oxygenation index
timeFrame: perioperative period
Secondary outcomes:
measure: alterations in cytokine and ROS in the perioperative period
timeFrame: perioperative period
measure: extubation time
timeFrame: perioperative period
measure: complications of vital organs
timeFrame: perioperative period
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
state: Beijing
Study officials:
affiliation: Beijing Anzhen Hospital
name: Weiping Weiping
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03542331: Endometrial Effects of Lipiodol
Official title: Histological and Transcriptional Changes Caused by Endometrial Flushing With Lipiodol: A Cross Over Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Female Infertility
Lead sponsor: Universitair Ziekenhuis Brussel
Sponsor class: OTHER
First posted: 2018-05-31
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The goal is to investigate whether endometrial flushing with Lipiodol enhances fertility. Therefore, anatomo-pathological, histochemical and transcriptional changes of the endometrium after Lipiodol bathing in a general population of healthy volunteers will be determined.

Detailed description: A single-centre, cross-over, open-label trial will be performed. Healthy volunteers, fulfilling the inclusion/exclusion criteria, will be asked to do blood samples and ultrasounds for the detection of the LH (luteinizing hormone) surge in a natural cycle. The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle, while the control group between day 6 and 8 of the cycle will have a mock catheter introduction without any Lipiodol flush. An endometrial biopsy will be performed 7 days after the LH peak in all the participants. Furthermore, all the participants will undergo one cycle with flushing and one cycle with introduction of a mock catheter but without flushing with any medication. The wash-out period between the 2 biopsies will be 3 months.

Eligibility criteria: Inclusion Criteria:

* Women aged ≥18 and \<36 years
* Regular cycle (25-35 days)
* Signed informed consent
* Participants can be included only once in the trial
* Contraceptive: barrier method only.

Exclusion Criteria:

* known iodine allergy
* Body mass index 30 or ≤18.5
* Smoking
* Previous diagnosis of PCO (Polycystic Ovary Syndrome) (\>12 antral follicles in one ovary, Rotterdam criteria 2003)
* Previous diagnosis of endometriosis, uterine malformations or intrauterine pathologies (submucosal fibroids, endometrial polyps, and intrauterine adhesions)
* Systemic diseases such as thyroid dysfunction
* Breast-feeding or pregnancy within the last 6 months
* Intrauterine devices (IUD)
* History of recurrent miscarriage
* Known history of infertility
* Previous uterine surgery
* Pregnancy wish during the course of the study
* Women who have been previously enrolled in the trial
* Those unable to comprehend the investigational nature of the proposed study

Primary outcomes:
measure: Anatomo-pathological changes of the endometrium after Lipiodol bathing
timeFrame: 7 days after LH peak
measure: Histochemical changes of the endometrium after Lipiodol bathing
timeFrame: 7 days after LH peak
measure: Transcriptional changes of the endometrium after Lipiodol bathing
timeFrame: 7 days after LH peak
Secondary outcomes:
Other outcomes:
Locations:
city: Brussel
country: Belgium
facility: Universitair Ziekenhuis Brussel
Study officials:
References:
Clinical trial NCT01851031: A New Surgical Approach to Treat Medial or Low Condylar Fractures
Official title: A New Surgical Approach to Treat Medial or Low Condylar Fractures:The Minor Parotid Anterior Approach
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fracture of Condylar Process
Keywords: medial or low condylar fractures
the minor parotid anterior approach
the retromandibular approach
Lead sponsor: West China College of Stomatology
Sponsor class: OTHER
First posted: 2013-05-10
Enrollment: 60
Sex: ALL
Minimum age (years): 5
Maximum age (years): 56
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the study was to compare the new approach and the retromandibular approach, so that the therapeutic effect and the advantages of the new approach would be clear.

Detailed description: Sixty patients (72 sides) with medial or low condylar fractures were treated with surgical intervention. Thirty-six patients (42 sides) were treated with minor parotid anterior approach, and the other 24 patients (30 sides) were treated with retromandibular approach. The data about the operations and complications were recorded. The follow-up periods were 3-12 months.

Eligibility criteria: Inclusion Criteria:

* (1)clinical and imaging diagnosis of medial or low condylar fractures
* (2)bone fragments that were obviously dislocated, that affected patients appearance and function, requiring surgical intervention
* (3)no previous surgical treatment

Exclusion Criteria:

* (1)medial or low condylar fractures without obvious displacement
* (2)patients who had previously undergone unsuccessful surgery
* (3)the surgical site had traumatic scar, so the approach could be carried out on the original incision

Primary outcomes:
measure: the number of participants with facial nerve injury
timeFrame: from 3 months to 1 year after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China College of Stomatology
state: Sichuan
Study officials:
affiliation: West China College of Stomatology
name: Jia Hou, DMD
role: STUDY_CHAIR
References:
citation: Tang W, Gao C, Long J, Lin Y, Wang H, Liu L, Tian W. Application of modified retromandibular approach indirectly from the anterior edge of the parotid gland in the surgical treatment of condylar fracture. J Oral Maxillofac Surg. 2009 Mar;67(3):552-8. doi: 10.1016/j.joms.2008.06.066.
citation: Hou J, Chen L, Wang T, Jing W, Tang W, Long J, Tian W, Liu L. A new surgical approach to treat medial or low condylar fractures: the minor parotid anterior approach. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Mar;117(3):283-8. doi: 10.1016/j.oooo.2013.11.491. Epub 2013 Nov 18.
Clinical trial NCT04306731: Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.
Official title: A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Use of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Recurrent Urinary Tract Infection
Keywords: nanotechnology water, antibiotic prophylaxis, recurrent UTI.
Lead sponsor: University of Sulaimani
Sponsor class: OTHER
First posted: 2020-03-13
Enrollment: 437
Sex: FEMALE
Minimum age (years): 24
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study investigates nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females.

Detailed description: This study represents the first time to use nanotechnology structured water magnalife in urology and to test its effects against lower urinary tract infections (UTI) in females. Urinary tract infection (UTI ) is the second most common bacterial infection, affecting women at a much higher frequency than men. There is a higher rate of recurrence of UTI, and a recurrent infection will follow 25-35% of initial UTI episodes within 3-6 months.

Intermittent or prolonged low dose antibiotic therapy has been used to treat and prevent recurrent UTI. Emerging of resistance to antimicrobial agents, enormous economic burden, and the side effects of antibiotics have led to the search for an alternative non-antibiotic prophylaxis of recurrent UTI. Nanotechnology structured water is a new type of drinking water that has been prepared using different types of energy fields and electromagnetic fields to produce this structured water, which has new and different characteristics from the ordinary water.

In the current study, the efficacy of nanotechnology structured water magnalife was compared with low-dose Trimethoprim and bottled drinking water for the prevention of recurrent UTI.

Eligibility criteria: Inclusion Criteria:

* ≥ 2 (two or more than two) UTI in the last 6 months
* ≥ 3 (three or more than three) UTI in the last 12 months

Exclusion Criteria:

* immunotherapy
* radiotherapy
* malignancy
* steroids
* chronic infections
* chemotherapy
* immunosuppressive drugs
* anatomical abnormality of the urinary tract
* surgical operation the urinary tract

Primary outcomes:
measure: Recurrent Urinary Tract Infection
timeFrame: Twelve months
Secondary outcomes:
measure: Time to first recurrent UTI
timeFrame: Twelve months
Other outcomes:
Locations:
city: Sulaymaniyah
country: Iraq
facility: College of Medicine, University of Sulaimani
state: Kurdistan Region
Study officials:
affiliation: College of Medicine, University of Sulaimani
name: Ali K M.Sami, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: